Factbox-Global pharma companies that have publicly announced Trump drug pricing agreements

16 major pharmaceutical companies agreed to align U.S. prescription drug prices with those in other developed nations in exchange for three-year tariff exemptions. Reported discounts include Pfizer average savings ~50% (up to 85%), Novo Nordisk cutting Ozempic/Wegovy to $350/month from $1,000/$1,350 and insulin to $35/month, and Merck offering key diabetes drugs ~70% off list; multiple firms pledged similar 60–85% discounts and direct-to-consumer availability via TrumpRx.gov. The deals are sector-moving: they reduce U.S. patient costs and could materially pressure pharma pricing power and revenue while creating policy and Medicaid pricing implications; Regeneron has not yet signed.

Analysis

This deal set converts political leverage into an ongoing US price ceiling for a large swath of marketed therapies, shifting value from headline list prices into volume, access programs, and political goodwill. Expect immediate margin compression on high-priced specialty drugs (GLP-1s, obesity, some biologics) — a realistic working assumption is peak-US price cuts of 50-70% on affected products, which knocks 20–40% off peak sales NPV for those franchises and can translate to ~1–3 turns of multiple compression for exposed names over 6–12 months.

Second-order winners are companies and channels that can monetize scale and direct-to-patient flows (in-house DTP platforms, low-cost manufacturing, insulin/commodity biologic producers), and losers are intermediaries that capture spread (some PBMs, specialty pharmacies, and distributors) whose fee pools will be renegotiated. Supply-chain effects: higher on-shore fill volumes and increased direct-ship logistics will boost contract manufacturing and cold-chain demand but reduce wholesaler gross margins — expect a 6–18 month bump in CDMO/3PL revenues but a multi-year structural haircut to distributor EBITDA margins.

Tail risks cluster around policy durability and legal pushback — deals are voluntary and contingent on tariff waivers, so a change in administration, litigation, or a renegotiation of exemption terms could reprice the sector within weeks. Monitor three catalysts: (1) timeline for new-drug launch-price commitments (sets forward-looking NPV), (2) CMS/state follow-on legislation using these deals as precedent (6–24 months), and (3) PBM/Specialty pharmacy contract renegotiations (0–12 months) that will reallocate cashflows across the channel.

Key Decisions for Investors

• Pair trade (6–12 months): Short LLY (0.55 negative) vs Long NVS (−0.05 negative) — equal-dollar. Rationale: LLY’s obesity/GLP-1 exposure faces outsized margin loss; NVS has diversified geographies and lower GLP-1 concentration. Target relative outperformance of 20–30%; stop-loss: 12% on the pair if LLY rallies on unexpected demand/data; expected payoff asymmetric if parity pricing persists.
• Short Novo Nordisk (NVO) via Jan-2027 puts sized for 3–5% portfolio risk (6–18 months): GLP-1 pricing cut assumed to reduce peak sales by ~30–50%, creating tail downside if volume fails to offset price. Risk: rapid market share gains or new higher-dose formulations could re-expand pricing power; cap position sizing accordingly.
• Long CDMO/3PL exposure (buy selective names in the healthcare supply chain outside this list) for 12–18 months — benefit from higher direct-to-patient shipments and on-shore manufacturing demand. Tactical entry on any post-announcement pullback of 5–10%; target 25–40% upside as volumes shift, with stop at 15% drawdown.
• Event hedge (0–12 months): Buy a basket of cheap OTC put protection on broadly exposed large-cap pharma (PFE/JNJ/ABBV) equal to 0.5–1% portfolio risk to guard against a legal or legislative escalation that further compresses multiples. This is insurance: cost likely <1% annualized for downside protection across the sector.